When will ixazomib be launched? Has it been launched in China?

Ixazomib is a prescription drug. Ixazomib n>Approved the first oral proteasome inhibitor (PI) for the treatment of multiple myeloma in combination with 2 other therapies (lenalidomide and dexamethasone) in patients who have received at least 1 prior therapy. Ixazomib was launched in China in December 2016.

Ixazomib is an N-terminal dipeptidyl leucine boronic acid that reversibly inhibits the CT-L proteolytic (β5) site of the proteasome. At higher concentrations, ixazomib also appears to inhibit the proteolytic β1 and β2 subunits and induce the accumulation of ubiquitinated proteins. After oral administration, the time to reach maximum concentration in plasma is 1hour, and the mean absolute oral bioavailability is 58%.

It is expected that ixazomib will be metabolized via CYP and nonCYP pathways, without major CYP isoenzymes. At higher than clinical concentrations, ixazomib is metabolized by multiple CYP isomers, with an estimated relative contribution of 3 a4 (42%), 1 a2（26%）, 2b 6（16%), 2 c8（6%）, 2d 6（5%), 2c 19 (5%) and 2c 9 (《1%). 62%in urine, 22%in feces. The terminal half-life is 9.5 days. Avoid use of St. John's wort, which induces CYP3A4 metabolism, which may decrease serum concentrations of ixazomib . On an empty stomach, food increases the absorption of ixazomib , take the dose of ixazomib at least one hour before and at least two hours after eating. The retail price of Lucius Pharmaceuticals in Laos 4mg*3 tablets 900yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.